Abstract
Abstract
Objectives
The aim of this proof-of-principle study combining data analysis and computer simulation was to evaluate the robustness of apparent diffusion coefficient (ADC) values for lymph node classification in prostate cancer under conditions comparable to clinical practice.
Materials and methods
To assess differences in ADC and inter-rater variability, ADC values of 359 lymph nodes in 101 patients undergoing simultaneous prostate-specific membrane antigen (PSMA)-PET/MRI were retrospectively measured by two blinded readers and compared in a node-by-node analysis with respect to lymph node status. In addition, a phantom and 13 patients with 86 lymph nodes were prospectively measured on two different MRI scanners to analyze inter-scanner agreement. To estimate the diagnostic quality of the ADC in real-world application, a computer simulation was used to emulate the blurring caused by scanner and reader variability. To account for intra-individual correlation, the statistical analyses and simulations were based on linear mixed models.
Results
The mean ADC of lymph nodes showing PSMA signals in PET was markedly lower (0.77 × 10−3 mm2/s) compared to inconspicuous nodes (1.46 × 10−3 mm2/s, p < 0.001). High inter-reader agreement was observed for ADC measurements (ICC 0.93, 95%CI [0.92, 0.95]). Good inter-scanner agreement was observed in the phantom study and confirmed in vivo (ICC 0.89, 95%CI [0.84, 0.93]). With a median AUC of 0.95 (95%CI [0.92, 0.97]), the simulation study confirmed the diagnostic potential of ADC for lymph node classification in prostate cancer.
Conclusion
Our model-based simulation approach implicates a high potential of ADC for lymph node classification in prostate cancer, even when inter-rater and inter-scanner variability are considered.
Clinical relevance statement
The ADC value shows a high diagnostic potential for lymph node classification in prostate cancer. The robustness to scanner and reader variability implicates that this easy to measure and widely available method could be readily integrated into clinical routine.
Key Points
• The diagnostic value of the apparent diffusion coefficient (ADC) for lymph node classification in prostate cancer is unclear in the light of inter-rater and inter-scanner variability.
• Metastatic and inconspicuous lymph nodes differ significantly in ADC, resulting in a high diagnostic potential that is robust to inter-scanner and inter-rater variability.
• ADC has a high potential for lymph node classification in prostate cancer that is maintained under conditions comparable to clinical practice.
Graphical abstract
Funder
Westfälische Wilhelms-Universität Münster
Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging,General Medicine
Reference35 articles.
1. Wild CP, Weiderpass E, Stewart BW, editors (2020) World Cancer Report: cancer research for cancer prevention. Lyon, France: International Agency for Research on Cancer. Available from: http://publications.iarc.fr/586. Licence: CC BY-NC-ND 3.0 IGO
2. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Prostatakarzinom Langversion 6.2, 2021, AWMF Registernummer: 043/022OL. Available via http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/. Accessed 23 May 2023
3. Brand DH, Parker JI, Dearnaley DP et al (2019) Patterns of recurrence after prostate bed radiotherapy. Radiother Oncol 141:174–180
4. Öbek C, Doğanca T, Demirci E et al (2017) The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer. Eur J Nucl Med Mol Imaging 44:1806–1812
5. Jilg CA, Drendel V, Rischke C et al (2017) Diagnostic accuracy of Ga-68-HBED-CC-PSMA-ligand-PET/CT before salvage lymph node dissection for recurrent prostate cancer. Theranostics 7:1770–1780